NCT00796432View on ClinicalTrials.gov

A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

June 30, 2003

Conditions
Schizophrenia
Interventions
DRUG

OROS paliperidone

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00796432 - A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone | Biotech Hunter | Biotech Hunter